March 14, 2013 – FDA announces investigation into pancreatic cancer risk with Onglyza and other incretin mimetic diabetes drugs.
March 2013 – Cancer risk investigation launched
Announcement Date: March 14, 2013
March 14, 2013 – FDA announces investigation into pancreatic cancer risk with Onglyza and other incretin mimetic diabetes drugs.